AVTR - Avantor, Inc.
RADNOR, Pa., May 19, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced that Gerard (Jerry) Porreca has joined the company as Executive Vice President, Quality and Regulatory.
AVTR benefits from stable Q1 revenues and improving demand trends, though margin pressure and volume softness weigh on profitability.
Avantor, Inc. reported a slight beat on 1Q26 EPS and revenue, but underlying organic growth and margins remain under pressure. Negative organic growth, margin compression, and subdued cash flow signal only early stabilization, not a confirmed recovery, especially in the VWR segment. Management reaffirmed 2026 guidance and expects sequential improvement, but the recovery is execution-dependent and gradual, with margins likely to remain below historical peaks.
Avantor, Inc. (AVTR) Q1 2026 Earnings Call Transcript
Avantor, Inc. (AVTR) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.23 per share a year ago.
Net sales of $1,581 million Net income of $43 million; Adjusted EBITDA of $219 million Diluted GAAP EPS of $0.06; adjusted EPS of $0.17 Operating cash flow of $59 million; free cash flow of $25 million Reaffirms FY 2026 guidance RADNOR, Pa., April 29, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its first fiscal quarter ended March 31, 2026.
RADNOR, Pa., April 23, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced that Ludovic Brellier will join the company as Executive Vice President, Bioscience & Medtech Products (BMP) & Chief Transformation Officer on May 1, 2026.
AVTR expands Masterflex across its fluid handling portfolio, aiming to streamline workflows and boost scalable bioprocessing adoption.
NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Avantor, Inc. (NYSE: AVTR) breached their fiduciary duties to shareholders.
Portfolio now includes standard, configurable, and engineered-to-order peristaltic pumps, single-use assemblies, and systems for R&D through high-volume manufacturing Company to attend INTERPHEX 2026 in New York City from April 21-23 RADNOR, Pa., April 21, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to the life sciences and advanced technology industries, today announced the expansion of its Masterflex brand across its fluid handling portfolio, bringing together standard, configurable, and engineered-to-order peristaltic pumps, single-use assemblies, and systems.
During the quarter, we had no new purchases and exited three holdings: Louisiana-Pacific, PayPal and Walt Disney. CNH, a leading global agriculture and construction equipment manufacturer, was a contributor for the quarter. Life-sciences company Avantor detracted for the quarter.
AVTR stock gains after expanding U.S. lab capabilities, boosting biopharma support, streamlining testing and strengthening supply chain efficiency.
St. Louis site strengthens integrated support for biopharma manufacturing RADNOR, Pa., April 13, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced the expansion of its North American quality control capabilities with the addition of advanced microbial and stability testing at its St. Louis manufacturing site.
First Choice Healthcare Solutions (OTCMKTS:FCHS - Get Free Report) and Avantor (NYSE: AVTR - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations. Insider and Institutional Ownership 95.1% of Avantor
RADNOR, Pa., April 3, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its first quarter 2026 financial results before the market opens on Wednesday, April 29, and will hold a conference call to discuss the results on the same day at 8:00 a.m.
RADNOR, Pa., April 1, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced that Executive Vice President and Chief Financial Officer (CFO), R.
XWELL (NASDAQ: XWEL - Get Free Report) and Avantor (NYSE: AVTR - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability. Valuation and Earnings This table compares XWELL and Avantor"s top-line
Circumference Group initiated a new position in Avantor, buying up 305,000 shares during the fourth quarter. The quarter-end position value increased by $3.50 million, reflecting the purchase of the 305,000 shares.
Shares of Avantor, Inc. (NYSE: AVTR - Get Free Report) have been assigned an average rating of "Hold" from the sixteen brokerages that are covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a sell recommendation, ten have assigned a hold recommendation and three have issued a buy recommendation on the
AVTR, COIN and CMG have been added to the Zacks Rank #5 (Strong Sell) List on March 17, 2026.